Abstract
Signal transduction therapy for cancer targets pathways that are over-active in cancer cells and upon which the cancer cells depend for their survival. Protein kinases are prime targets for signal transduction therapy. A major breakthrough was the introduction of the Bcr-Abl inhibitor imatinib/Gleevec into the clinic for the treatment of chronic myelogenous leukemia (CML). Nevertheless, even for this clonal disease, which has a well-characterized principle survival factor, signal transduction therapy faces two major problems: the emergence of drug-resistant clones and the persistence of a small population of cancer stem cells that re-establish the leukemia if treatment is stopped. Most cancers are far more heterogeneous than CML, so choosing the appropriate molecular targets is a major challenge. Signal transduction therapy can potentially reduce tumor mass and control cancer as a chronic disease. Complete cures will require ways of combating cancer stem cells and preventing metastasis, such as harnessing bystander effects and the immune system during treatment.
Keywords: Signal transduction therapy, kinase inhibitor, cancer
Current Signal Transduction Therapy
Title: Signal Transduction Therapy for Cancer - Whither Now?
Volume: 1 Issue: 1
Author(s): Shoshana Klein and Alexander Levitzki
Affiliation:
Keywords: Signal transduction therapy, kinase inhibitor, cancer
Abstract: Signal transduction therapy for cancer targets pathways that are over-active in cancer cells and upon which the cancer cells depend for their survival. Protein kinases are prime targets for signal transduction therapy. A major breakthrough was the introduction of the Bcr-Abl inhibitor imatinib/Gleevec into the clinic for the treatment of chronic myelogenous leukemia (CML). Nevertheless, even for this clonal disease, which has a well-characterized principle survival factor, signal transduction therapy faces two major problems: the emergence of drug-resistant clones and the persistence of a small population of cancer stem cells that re-establish the leukemia if treatment is stopped. Most cancers are far more heterogeneous than CML, so choosing the appropriate molecular targets is a major challenge. Signal transduction therapy can potentially reduce tumor mass and control cancer as a chronic disease. Complete cures will require ways of combating cancer stem cells and preventing metastasis, such as harnessing bystander effects and the immune system during treatment.
Export Options
About this article
Cite this article as:
Klein Shoshana and Levitzki Alexander, Signal Transduction Therapy for Cancer - Whither Now?, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269244
DOI https://dx.doi.org/10.2174/157436206775269244 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Modern drug delivery systems for targeting the posterior segment of the eye
Current Pharmaceutical Design Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Dysregulated Pathway Identification of Alzheimer's Disease Based on Internal Correlation Analysis of Genes and Pathways
Combinatorial Chemistry & High Throughput Screening Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Topoisomerases and Tubulin Inhibitors: A Promising Combination for Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Adenovirus As An Integrating Vector
Current Gene Therapy New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Synthesis of 6-Aryl-2,11-dihydro-3H-pyrrolo[1,2-e][1,2,4]triazolo[4,3-b] [1,2,5]triazepin-3-ones
Letters in Organic Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Metabolic Fate of Endocannabinoids
Current Neuropharmacology Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms
Current Drug Targets